News

Join JYMed at CPHI South East Asia 2025

We’re excited to join industry leaders at CPHI South East Asia 2025, happening from July 16 to 18 at MITEC in Kuala Lumpur. The event spans over 15,000 square meters and will feature around 400 exhibitors. More than 8,000 professionals are expected to attend, along with 60+ seminars and forums f... Read More

CPHI ShangHai 2025

From June 24 to 26, 2025, the 23rd CPhI China was successfully held at the Shanghai New International Expo Centre!JYMed President Mr. Yao Zhiyong, together with the company’s senior leadership team, attended the event in person. The team engaged directly with the full lifecycle of GLP-1 peptide ... Read More

Meet JYMed at Interphex Week Tokyo 2025

We’re excited to announce that JYMed will be exhibiting at Interphex Week Tokyo from July 9 to 11, 2025, at Tokyo Big Sight (Ariake). This major event brings together over 90 exhibitors and approximately 34,000 professionals from across the pharmaceutical and cosmetics industries. As one of Asia’... Read More

Join JYMed at CPHI China 2025

CPHI China 2025 will take place from June 24–26, 2025, at the Shanghai New International Expo Centre (SNIEC). Spanning more than 230,000 square meters, the event is set to host over 3,500 exhibitors and attract more than 100,000 industry professionals. As one of Asia’s largest and most influenti... Read More

JYMED’S PEPTIDE PRODUCTION BASE IN HUBEI PASSES SECOND CONSECUTIVE FDA INSPECTION

Hubei JXBio Pharmaceutical Co., Ltd., JYMed’s dedicated peptide production site, successfully completed another on-site inspection by the U.S. Food and Drug Administration (FDA) from March 10-14. The inspection, part of a Drug Quality Assurance audit, evaluated key systems including quality, prod... Read More

JYMED PEPTIDE RECEIVES THREE QUALITY CERTIFICATIONS

JYMed has implemented a robust quality management system, earning three certifications for consistently delivering products and services that meet global standards.The achievement of ISO 9001 certification demonstrates that the company has well-defined processes and standards for internal managem... Read More

MEET JYMED AT 3 GLOBAL EVENTS IN 2025

We’re excited to join ExpoFarma (Mexico City), IPhEB (St. Petersburg), and In-Cosmetics Global (Amsterdam) in 2025. Come connect with our team and explore collaboration opportunities.   Expo Farma 2025 Dates: April 2–4, 2025 Location: World Trade Center, Mexico City Hosted by the Asociación... Read More

EUROPEAN PATENT GRANTED FOR LIRAGLUTIDE SYNTHESIS

JYMed has been awarded a European patent for its innovative synthesis method of Liraglutide. This milestone highlights our continued leadership in peptide R&D and IP. This patent represents a new process for synthesizing liraglutide, which not only ensures stable yield but also significantly ... Read More

Exciting News | JYMed Secures DMF Filings for Five New Products in the U.S.

Recently, Shenzhen JYMed Technology Co., Ltd. (hereinafter referred to as “JYMed”) has successfully completed Drug Master File (DMF) filings for five additional products with the U.S. Food and Drug Administration (FDA), further expanding its product portfolio. ABOUT JYMED JYMed is a... Read More

JYMED Invites You to PCHi 2025 in Guangzhou

JYMED sincerely invites you to join us at the 2025 PCHi Cosmetic Ingredients Exhibition in Guangzhou to explore the latest market trends, innovative technologies, and international regulations. Visit us at Booth 6J07!     The 2025 Guangzhou PCHi Exhibition will be held from February 19... Read More

Exciting News | JYMed’s Peptide Production Facility Receives WC Certification

Recently, JYMed’s peptide production facility, Hubei Jianxiang Biopharmaceutical Co., Ltd., received two official documents issued by the Hubei Provincial Drug Administration: the “Drug GMP Compliance Inspection Result Notification” (No. E GMP 2024-258 and No. E GMP 2024-260) a... Read More

Exciting News | China’s Largest Semaglutide API Production Facility Passes U.S. FDA Inspection

From August 26 to August 30, 2024, JYMed’s peptide production facility, Hubei JX Bio-Pharmaceutical Co., Ltd., successfully passed an on-site inspection conducted by the U.S. Food and Drug Administration (FDA). The inspection covered key areas such as the quality system, production system, e... Read More

2024 CPHI Milan Pharmaceutical Exhibition Recap

01. Exhibition Overview On October 8th, the 2024 CPHI Worldwide Pharmaceutical Exhibition kicked off in Milan. As one of the most important annual events in the global pharmaceutical industry, it attracted participants from 166 countries and regions. With over 2,400 exhibitors and 62,000 professi... Read More

Exciting News | JYMed’s Liraglutide API Receives WC Certification

On October 12, 2024, JYMed’s Liraglutide API obtained the Written Confirmation (WC) certificate, marking a critical step toward the successful export of the API to the EU market. The WC (Written Confirmation) is a mandatory requirement for the export of APIs from non-EU countries to the... Read More

Exciting News: JYMed’s Leuprorelin Acetate Passes Drug Registration Inspection

Recently, JYMed Technology Co., Ltd. announced that Leuprorelin Acetate, produced by its subsidiary Hubei JX Bio-Pharmaceutical Co., Ltd., has successfully passed the drug registration inspection. Original Drug Market Overview Leuprorelin Acetate is an injectable medication used to trea... Read More

Congratutlation JYMed’s Tirzepatide Completes US-DMF Filing

JYMed Technology Co., Ltd. is pleased to announce that its product, Tirzepatide, has successfully completed the Drug Master File (DMF) registration with the U.S. FDA (DMF Number: 040115) and received the FDA’s Acknowledgement on August 2, 2024. Mass Production with Stable Quality ... Read More

JYMed Attends PCT 2024 in Shanghai

PCT2024 Personal Care Technology Summit & Exhibition is a highly influential event in the Asia-Pacific region, focusing on technology exchange and exhibitions in the personal care products industry.The forum will cover various aspects of the personal care industry, including technological in... Read More

JYMed Peptide Invites You to Attend the 2024 Korea In-cosmetics Ingredients Exhibition

  Location: Korea International Exhibition Center Date: July 24-26, 2024 Time: 10:00 AM – 5:00 PM Address: COEX Exhibition Center Hall C, 513 Yeongdong-daero, Gangnam-gu, Seoul, 06164   In-cosmetics is a leading international exhibition group in the personal care ingredien... Read More

New Regulation Bulletin

1. New FDA Registration Regulations for U.S. Cosmetics Cosmetics Without FDA Registration Will Be Banned from Sale.According to the Modernization of Cosmetics Regulation Act of 2022, signed by President Biden on December 29, 2022, all cosmetics exported to the United States must be FDA-registere... Read More

Spring Festival Holiday Notice

Please kindly be informed that our office will be closed from Feb. 4 to Feb.18 due to the Spring Festival. Any orders will be accepted but will not be processed until Feb.19, the first business day after the Spring Festival. Sorry for any inconvenience caused.     Read More
12 Next > >> Page 1 / 2